NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on developing antiviral drugs, has announced that a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP to initiate the trial and has appointed Professor Patrick Katoto as the principal investigator. Preparatory work, including staff training, is already underway, and the NV-387 drug product is available in the DRC, with first patient dosing anticipated within a few weeks, barring any outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features that viruses require for infection. NanoViricides believes that oral delivery could offer significant advantages in resource-limited outbreak settings compared with treatments requiring intravenous infusions. This approach could simplify logistics and improve patient compliance, which is critical in managing Ebola outbreaks where healthcare infrastructure may be strained.
The trial will be conducted with Om Sai Clinical Research Private Limited serving as the contract research organization (CRO). This CRO will also support the company's planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC, indicating a broader strategy to address multiple viral threats with the same platform technology.
The significance of this development lies in the potential to provide a more accessible treatment for Ebola, which has historically been managed with injectable therapies that require cold chain storage and trained medical personnel. An oral formulation could be administered more easily in remote areas, potentially reducing mortality and curbing transmission. Moreover, the broad-spectrum nature of NV-387 means that successful trials could pave the way for its use against other viral infections, including Mpox, COVID-19, and influenza, as the company has indicated in its pipeline.
NanoViricides' lead drug candidate, NV-387, is being developed for multiple indications, including respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as Mpox/smallpox and measles. The company also has other candidates in development, such as NV-HHV-1 for shingles. The progression of NV-387 into Phase II trials marks a significant milestone for the company, which has been focused on advancing this candidate through clinical development.
The Ebola virus disease (EVD) remains a major public health concern in Africa, with periodic outbreaks causing high fatality rates. The current outbreak in the DRC involves the Bundibugyo strain, which has a lower mortality rate than the Zaire strain but still poses a serious threat. An effective oral treatment could significantly improve outbreak response efforts, reducing the burden on healthcare systems and improving patient outcomes.
NanoViricides' technology is based on the TheraCour nanomedicine platform, which the company licenses from TheraCour Pharma. The company holds exclusive, perpetual licenses to develop drugs for a range of viral diseases, including HIV, hepatitis B and C, rabies, herpes, influenza, dengue, Japanese encephalitis, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses. This broad licensing portfolio provides a strong foundation for future drug development.
While the company is optimistic about the potential of NV-387, it also acknowledges the inherent risks in drug development. The path to regulatory approval is lengthy and requires substantial capital, and there is no guarantee that the drug will demonstrate sufficient efficacy and safety in clinical trials. However, the start of the Phase II trial in the DRC is a concrete step forward in addressing a critical unmet medical need.
For more information about NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC.
